Jefferies Raises Numbers on AbbVie as Products Squeeze the Competition (ABBV)

On Monday analysts at Jefferies boosted its price target and estimates on pharmaceutical company AbbVie Inc (ABBV) as various drugs, such as Humira, continue to perform well.

The analysts increased earning estimates on ABBV and now see shares reaching $45, which suggests a +21% upside to Friday’s closing price. The firm maintained a “Buy” rating on AbbVie.

AbbVie shares were down 58 cents, or -1.56%, during pre-market trading on Monday. The stock is up +8.84% since it was spun off from Abbot Labs in early January 2013.

The Bottom Line
Shares of AbbVie (ABBV) have a dividend yield of 4.30% based on Friday’s closing price of $37.18.

AbbVie Inc (ABBV) is recommended at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here